- Home
- NEWP vs MOLN Comparison
NEWP vs MOLN Comparison
Compare NEWP & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- MOLN
- Stock Information
- Founded
- NEWP 1972
- MOLN 2004
- Country
- NEWP Canada
- MOLN Switzerland
- Employees
- NEWP N/A
- MOLN N/A
- Industry
- NEWP
- MOLN
- Sector
- NEWP
- MOLN
- Exchange
- NEWP Nasdaq
- MOLN Nasdaq
- Market Cap
- NEWP 262.4M
- MOLN 214.4M
- IPO Year
- NEWP N/A
- MOLN 2021
- Fundamental
- Price
- NEWP $1.33
- MOLN $5.31
- Analyst Decision
- NEWP Strong Buy
- MOLN
- Analyst Count
- NEWP 1
- MOLN 0
- Target Price
- NEWP $5.00
- MOLN N/A
- AVG Volume (30 Days)
- NEWP 215.8K
- MOLN 26.7K
- Earning Date
- NEWP 02-11-2025
- MOLN 08-26-2024
- Dividend Yield
- NEWP N/A
- MOLN N/A
- EPS Growth
- NEWP N/A
- MOLN N/A
- EPS
- NEWP N/A
- MOLN N/A
- Revenue
- NEWP N/A
- MOLN $7,105,397.00
- Revenue This Year
- NEWP N/A
- MOLN N/A
- Revenue Next Year
- NEWP N/A
- MOLN $29.41
- P/E Ratio
- NEWP N/A
- MOLN N/A
- Revenue Growth
- NEWP N/A
- MOLN N/A
- 52 Week Low
- NEWP $0.87
- MOLN $3.32
- 52 Week High
- NEWP $2.53
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- NEWP 36.65
- MOLN 43.84
- Support Level
- NEWP $1.34
- MOLN $5.26
- Resistance Level
- NEWP $1.60
- MOLN $5.65
- Average True Range (ATR)
- NEWP 0.08
- MOLN 0.20
- MACD
- NEWP -0.02
- MOLN -0.04
- Stochastic Oscillator
- NEWP 11.17
- MOLN 6.85
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.